Biologic Solutions for Cardiac and Vascular Surgeons.
Make patient care more predictable and manageable with the extracellular matrix (ECM) that remodels into healthy, site-specific tissue.3,4,5,6,10,11
Reduce Risk. Naturally.
We help Cardiac & Vascular surgeons repair tissue with fewer complications.
Reducing complications and risk may make patient care more predictable and manageable. An extracellular matrix derived from porcine small intestine submucosa (SIS), our bioscaffold regulates the biologic healing response to decrease inflammation and stimulate formation of healthy tissue. 2,6
“The host response to biomaterials is a critical determinant of their success or failure in tissue-repair applications.”
Dziki JL, et al. J Biomed Mater Res A. 2017;105(1):138–147.
How Aziyo Helps.
Stephen F. Badylak, DVM, PhD, MD
Deputy Director, McGowan Institute for Regenerative Medicine, University of Pittsburgh
ECM regulates healing.
When sutured to viable tissue, Aziyo ECM products have a potential to remodel into site specific tissue.2,6,10,11 After implantation, SIS ECM remodels and reduces inflammation and stimulates angiogenesis.6,10,11 The transformation of SIS ECM into site-specific tissue may offer long-term benefits including facilitating reoperation if needed.4,5 Learn how SIS ECM reduces inflammation and remodels into site-specific tissue from tissue engineering expert Dr. Badylak.
ECM. How It Works.
The Body’s Reaction
When a device or foreign material is implanted in a patient, their immune response either integrates and remodels it into healthy tissue or induces prolonged inflammation that may result in the formation of fibrotic tissue. While the former is more desirable, the latter is too common.
Stephen F. Badylak, DVM, PhD, MD
Deputy Director, McGowan Institute for Regenerative Medicine, University of Pittsburgh
Minimize Inflammation
To minimize inflammation (and the associated complications) and achieve optimal tissue remodeling outcomes in patients, we’ve constructed ProxiCor PC, ProxiCor CTR and VasCure using multilaminate sheets of decellularized, non-crosslinked, lyophilized small intestinal submucosa (SIS). SIS ECM is associated with biologic activity such as recruitment of endogenous stem/progenitor cells and modulation of the host response to injury resulting in pro-remodeling, anti-inflammatory tissue growth.6
Healthy Tissue Growth
Phases of ECM Guided Wound Healing.
Inflammation
Inflammation involving M1 macrophages is an inherent component of healing. However, prolonged M1 macrophage function can cause chronic inflammation and lead to fibrosis and scarring. The presence of SIS ECM promotes a shift from M1 to a pro-remodeling, anti-inflammatory M2 phenotype.7
Proliferation
Concurrent with the inflammatory phase, in the proliferation phase fibroblasts populate the SIS ECM through attaching and proliferating.8 This stage is also marked by angiogenesis and epithelization which forms healthy vascularized tissue.8
Tissue Remodeling
As the SIS ECM is broken down and absorbed, the number of fibroblasts and macrophages in the matrix declines over time.7 Matrix turnover ultimately slows and eventually stops, ending angiogenesis.6 Scaffold remodeling is complete when metabolic activity stabilizes and the newly regenerated tissue becomes fully functional.7,8
Patient Success Story.
Lori Wisniewski
Cardiac surgery patient (ProxiCor CTR).
The surgery was performed July 11, 2011 and at the end of September I was able to complete a triathlon! About 6 months after the surgery, she had a routine transesophageal echo where it was difficult to discern a difference between the ProxiCor CTR bioscaffold and the adjacent heart tissue. No further tests have been required.
Cardiac & Vascular Products.
ProxiCor PC
ProxiCor for Pericardial Closure
ProxiCor CTR
ProxiCor for Cardiac Tissue Repair
VasCure
VasCure for Vascular Repair
Want to Receive Updates About Upcoming Webinars?
Click below to join our webinar mailing list.
1. Data on file at Aziyo Biologics, Inc.
2. Pre-clinical data on file at Aziyo Biologics, Inc.
3. Rego A, et al. J Cardiothorac Surg. 2019;14(1):61.
4. Shell D, et al. Ann Surg. 2005 Jun;241(6):995-1001; discussion 1001-4.
5. Gerdisch M, et al. J Thorac Cardiovasc Surg. 2014 Oct;148(4):1370-8.
6. Dziki JL, et al. J Biomed Mater Res A. 2017;105(1):138–147
7. Londono R, et al. Ann Biomed Eng. 2015; 43(3): 577-92.
8. Turner MD, et al. Biochim Biophys Acta. 2014;1843(11): 2563-82.
9. Tonnesen MG, et al. J Investig Dermatol Symp Proc. 2000;5(1):40-6.
10. Badylak SF, et al. J Surg Res. 2002 Apr;103(2):190-202.
11. Brennan EP, et al. Tissue Eng. 2006 Oct;12(10):2949-55.
WMK-1509-01B